About Arcus Biosciences, Inc.
https://www.arcusbio.comArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.
CEO
Terry J. Rosen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 155
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citigroup
Buy
Truist Securities
Buy
Wells Fargo
Overweight
Morgan Stanley
Overweight
Barclays
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
GILEAD SCIENCES, INC.
Shares:31.42M
Value:$771.79M
BLACKROCK, INC.
Shares:11.81M
Value:$290.07M
BLACKROCK INC.
Shares:9.76M
Value:$239.78M
Summary
Showing Top 3 of 221
About Arcus Biosciences, Inc.
https://www.arcusbio.comArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $26M ▼ | $166M ▼ | $-135M ▼ | -519.23% ▼ | $-1.27 ▼ | $-130M ▼ |
| Q2-2025 | $160M ▲ | $168M ▲ | $-8M ▲ | -5% ▲ | $0.04 ▲ | $4M ▲ |
| Q1-2025 | $28M ▲ | $150M ▲ | $-112M ▼ | -400% ▼ | $-1.14 ▼ | $-108M ▼ |
| Q4-2024 | $26M ▼ | $129M ▼ | $-94M ▼ | -361.54% ▼ | $-1.03 ▼ | $-89M |
| Q3-2024 | $48M | $153M | $-92M | -191.67% | $-1.01 | $-89M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $831M ▼ | $974M ▼ | $538M ▲ | $436M ▼ |
| Q2-2025 | $911M ▼ | $1.07B ▼ | $526M ▼ | $549M ▲ |
| Q1-2025 | $997M ▲ | $1.16B ▲ | $625M ▼ | $531M ▲ |
| Q4-2024 | $978M ▼ | $1.15B ▼ | $665M ▼ | $485M ▼ |
| Q3-2024 | $1.09B | $1.25B | $687M | $565M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-135M ▼ | $-97M ▲ | $79M ▼ | $8M ▼ | $-10M ▼ | $-97M ▲ |
| Q2-2025 | $0 ▲ | $-133M ▼ | $137M ▲ | $52M ▼ | $56M ▲ | $-133M |
| Q1-2025 | $-112M ▼ | $-132M ▼ | $32M ▼ | $142M ▲ | $42M ▲ | $-133M ▼ |
| Q4-2024 | $-94M ▼ | $-100M ▼ | $51M ▲ | $-2M ▼ | $-51M ▼ | $-101M ▼ |
| Q3-2024 | $-92M | $26M | $-29M | $48M | $45M | $25M |
Revenue by Products
| Product | Q4-2024 | Q3-2025 | Q2-2025 | Q1-2025 |
|---|---|---|---|---|
 License and Development Services Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $20.00M ▲ |
 License And RD Services | $0 ▲ | $190.00M ▲ | $190.00M ▲ | $0 ▼ |
 Other Collaboration Revenue | $20.00M ▲ | $0 ▼ | $0 ▲ | $10.00M ▲ |
 RD Services | $0 ▲ | $20.00M ▲ | $20.00M ▲ | $0 ▼ |
CEO
Terry J. Rosen
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 155
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
Citigroup
Buy
Truist Securities
Buy
Wells Fargo
Overweight
Morgan Stanley
Overweight
Barclays
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
GILEAD SCIENCES, INC.
Shares:31.42M
Value:$771.79M
BLACKROCK, INC.
Shares:11.81M
Value:$290.07M
BLACKROCK INC.
Shares:9.76M
Value:$239.78M
Summary
Showing Top 3 of 221